Biotechnology

Human Longevity's new low-cost whole genome sequencing promises predictive health for all, but its true power lies in its AI and a vast new data asset.

Exicure is settling a $1M debt with stock, a move to preserve its dwindling cash. Can this gamble save its new focus on blood cancer therapy or just delay the inevitable?

Ceruvia Lifesciences secures $8M for a non-hallucinogenic LSD analog to treat cluster headaches, offering a potential breakthrough for a severe pain disorder.

With $100M in total funding, bioinformatics firm Inocras plans to challenge U.S. precision oncology leaders by leveraging its whole-genome sequencing success in Asia.

Autolus Therapeutics reports a 100% year-over-year sales jump and a stunning gross margin reversal, securing a $250M credit facility to fund its next big move.

Biocon's Yesafili, an interchangeable biosimilar to the $5.9B eye drug Eylea, launches in the US, promising major cost savings and market disruption.

Fresh off a $260M IPO, Seaport Therapeutics is advancing a de-risked pipeline for depression and anxiety, leveraging its novel platform to unlock new potential.

Lipocine's appointment of M&A veteran Michael Grissinger isn't just a new face on the board; it's a clear signal of a strategic pivot towards high-stakes partnerships.

With blockbuster sales for its MS drug BRIUMVI, TG Therapeutics is raising revenue targets and aggressively expanding its pipeline into new diseases.

With its AI platform generating novel targets, Compugen advances a key ovarian cancer drug while partners AstraZeneca and Gilead push its discoveries forward.

The FDA has fast-tracked a novel peanut allergy therapy from Aravax, signaling a major shift in the multi-billion dollar race to find a lasting solution.

The first Animal Longevity Summit marks a pivotal moment, as research into pet aging and biotech investment converge to create a new frontier in healthspan.

NewcelX secured a small but vital $1.4M financing at a 20% premium. It's a bold vote of confidence, but is it enough to outrun a 'going concern' warning?

A new partnership aims to treat PTSD with psilocybin, revealing a broader strategy to navigate regulatory mazes and build the clinical infrastructure for a new era of medicine.

With cash dwindling and a pivotal trial result looming after a recent failure, Vistagen brings a seasoned drug developer aboard to navigate the turbulence.

Karyopharm's stock plummets after a key cancer trial fails, forcing a strategic retreat and a hard pivot toward more promising assets in its pipeline.

A landmark study validates Astrin Biosciences' proteomic test, Certitude, boasting >92% accuracy and offering new hope for women with dense breasts.

With $217M in the bank, SAB Biotherapeutics has silenced liquidity fears. Now, all eyes are on its novel T1D drug and the unproven promise of its cow-powered tech.

As Cellectar Biosciences preps its Q2 report, all eyes are on its cash runway and the immense promise of its targeted cancer therapy platform.

MIRA Pharmaceuticals moves two novel drug candidates closer to human trials, a key de-risking event for investors eyeing the massive pain and obesity markets.